Suppr超能文献

关于袢利尿剂在射血分数降低和射血分数保留的心力衰竭患者中的疗效和安全性的叙述性综述

A Narrative Review on the Efficacy and Safety of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction.

作者信息

Pius Ruth, Odukudu God-Dowell O, Olorundare Israel, Makanjuola Deborah I, Komolafe Rosemary, Njoku Chidimma, Ubogun Ogheneakpobor E, Muhammad Ramatu, Osiogo Elsie O, Anulaobi Caleb

机构信息

Internal Medicine, Lincoln Medical Centre, Bronx, USA.

Internal Medicine, Delta State University, Abraka, NGA.

出版信息

Cureus. 2023 Sep 22;15(9):e45794. doi: 10.7759/cureus.45794. eCollection 2023 Sep.

Abstract

To date, loop diuretics are the mainstay treatment for decongestion in patients with acute decompensated heart failure (HF). In clinical practice, loop diuretics have also been utilized for patients with chronic HF with reduced and preserved ejection fractions. There is a paucity of quality evidence of the effect of loop diuretics use and dosing on clinical outcomes in HF patients beyond symptomatic relief. In this review, we aimed to summarize recently published data on the use of loop diuretics in patients with HF, focusing on efficacy and safety outcomes in patients with HF with reduced and preserved ejection fraction. We searched EMBASE, PubMed, CINAHL, and the "Web of Science" databases. Cohort studies and randomized controlled trials published after 2018 and written in English were included in this review. Case reports, case series, cross-sectional studies, review articles, commentaries, articles published more than five years ago, and studies involving children were excluded. Results were divided into the efficacy and safety of loop diuretics in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). A registry-based study included in our review observed a reduced 30-day all-cause mortality in patients with HFrEF receiving loop diuretics compared to those not receiving loop diuretics (HR=0.73; 95% CI=0.57-0.94; p=0.016), but there was no statistically significant association at the 60-day follow-up of the same group of patients. Most studies reviewed showed that the choice of loop diuretics did not influence clinical outcomes such as mortality and HF rehospitalization in patients with HF with reduced and preserved ejection fraction despite differences in oral bioavailability and half-life. Studies have consistently shown that patients with HF who receive a higher dose of loop diuretics are likely to experience a decline in renal function and hypotension, regardless of their type of HF. Discontinuation or reduction of the dose of loop diuretics should be considered in patients with HF after decongestion.

摘要

迄今为止,袢利尿剂是急性失代偿性心力衰竭(HF)患者消肿治疗的主要手段。在临床实践中,袢利尿剂也已用于射血分数降低和保留的慢性HF患者。除了症状缓解外,关于袢利尿剂的使用和剂量对HF患者临床结局影响的高质量证据很少。在本综述中,我们旨在总结最近发表的关于HF患者使用袢利尿剂的数据,重点关注射血分数降低和保留的HF患者的疗效和安全性结局。我们检索了EMBASE、PubMed、CINAHL和“科学网”数据库。本综述纳入了2018年后发表且为英文撰写的队列研究和随机对照试验。排除病例报告、病例系列、横断面研究、综述文章、评论、五年多前发表的文章以及涉及儿童的研究。结果分为袢利尿剂在射血分数降低的心力衰竭(HFrEF)和射血分数保留的心力衰竭(HFpEF)中的疗效和安全性。我们综述中纳入的一项基于登记的研究观察到,与未接受袢利尿剂的HFrEF患者相比,接受袢利尿剂的患者30天全因死亡率降低(HR=0.73;95%CI=0.57-0.94;p=0.016),但在同一组患者的60天随访中,没有统计学上的显著关联。大多数综述研究表明,尽管口服生物利用度和半衰期存在差异,但袢利尿剂的选择并未影响射血分数降低和保留的HF患者的死亡率和HF再住院等临床结局。研究一致表明,接受高剂量袢利尿剂的HF患者肾功能下降和低血压的可能性更大,无论其HF类型如何。HF患者消肿后应考虑停用或减少袢利尿剂的剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d799/10590658/e3b7eeb54585/cureus-0015-00000045794-i01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验